CBG: The “Mother Cannabinoid” Explained

Overview

Cannabigerol (CBG) is a non-intoxicating cannabinoid that has gained attention in the hemp industry. Often called the "mother cannabinoid" because it serves as the chemical precursor to other cannabinoids, CBG is found in much smaller quantities than CBD or THC. This guide explains what CBG is, how it differs from other cannabinoids, and what current research shows about its potential properties.

What is CBG?

CBG is one of over 100 identified cannabinoids in the cannabis plant. Its significance lies in its role as a precursor compound. The acidic form of CBG (CBGA) is the first cannabinoid produced by the cannabis plant, and it converts into other cannabinoids as the plant matures [1].

The Cannabinoid Biosynthesis Pathway

The cannabis plant produces cannabinoids through a biosynthetic pathway:

1. CBGA (Cannabigerolic Acid) - The starting compound
2. CBGA is converted by enzymes into:

• THCA (which becomes THC when heated)
• CBDA (which becomes CBD when heated)
• CBCA (which becomes CBC when heated)

1. Some CBGA remains unconverted and becomes CBG when heated

This is why CBG is called the "mother cannabinoid"—CBGA is the parent compound from which other major cannabinoids are synthesized.

CBG Abundance in Cannabis

In most cannabis cultivars, CBG is present in very low concentrations:

CBG levels are highest in young cannabis plants before CBGA has been converted to other cannabinoids. By the time most plants are harvested, the majority of CBGA has already transformed into THCA, CBDA, or other compounds [2].

To produce CBG products, some cultivators have developed CBG-dominant strains or harvest plants at an earlier stage when CBG content is higher.

How CBG Differs from CBD and THC

Psychoactive Effects

CBG does not produce intoxicating effects. Unlike THC, CBG does not bind strongly to CB1 receptors in the brain that produce the "high" associated with cannabis [3].

Receptor Interactions

CBG interacts with both CB1 and CB2 receptors but with different affinity and action than THC or CBD. Research suggests CBG may also interact with other receptor systems, including alpha-2 adrenergic receptors and certain serotonin receptors [4].

Current Research on CBG

Research on CBG is still in early stages, with most studies conducted in cell cultures or animal models. No large-scale clinical trials have been completed in humans.

Preclinical Research Areas

Antibacterial Properties

A 2020 study found that CBG demonstrated antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) in laboratory settings. The cannabinoid showed promise against drug-resistant bacteria, though this has not been tested in human infections [5].

Neuroprotective Potential

Animal studies have investigated CBG's potential neuroprotective properties. A 2015 study in mice with Huntington's disease found that CBG improved motor deficits and preserved striatal neurons. These findings have not been replicated in humans [6].

Inflammation-related Effects

Laboratory studies suggest CBG may have inflammation-related properties. A 2013 study found that CBG reduced inflammation in a mouse model of inflammatory bowel disease [7]. Again, human studies are needed.

Appetite Stimulation

Unlike CBD, which may suppress appetite, a 2016 study in rats suggested CBG might stimulate appetite without producing intoxicating effects [8]. This could have implications for conditions involving appetite loss.

Glaucoma Research

Early research from the 1990s suggested cannabinoids including CBG might reduce intraocular pressure [9]. However, this research has not been extensively developed.

Important Caveats

When evaluating CBG research:

1. Most studies are preclinical: Cell culture and animal studies don't always translate to human effects
2. No FDA-authorized uses exist: Unlike CBD (in Epidiolex), CBG has no approved medical applications
3. Dosing is unknown: Effective doses for any condition have not been established
4. Long-term safety is unstudied: No long-term safety data exists for CBG supplementation

CBG Products

Types of CBG Products

CBG is available in formats similar to CBD products:

• Oils and tinctures
• Capsules
• Gummies and edibles
• Topicals
• Flower (CBG-dominant hemp strains)
• Isolate powders

What to Look For

When evaluating CBG products:

Cost Considerations

CBG products are typically more expensive than CBD products because:

• CBG is naturally present in lower concentrations
• Extraction requires more plant material
• CBG-dominant cultivars are less common

Comparing CBG to CBD

Legal Status

CBG derived from hemp (cannabis containing less than 0.3% Delta-9 THC) is federally legal under the 2018 Farm Bill. However, like other hemp-derived cannabinoids, state laws may vary. Some states have enacted restrictions on certain cannabinoid products [10].

Practical Considerations

If You're Considering CBG Products

1. Understand the evidence is preliminary: Research is in early stages
2. Don't expect proven medical benefits: No therapeutic claims are supported by clinical trials
3. Consult a healthcare provider: Especially if taking other medications
4. Verify product quality: Third-party testing is essential
5. Start with low doses: In the absence of dosing guidelines, begin conservatively

Drug Interactions

Like other cannabinoids, CBG may affect cytochrome P450 enzymes involved in metabolizing many medications. If you take prescription drugs, consult a healthcare provider before using CBG [11].

Drug Testing

CBG itself is not typically screened for in standard drug tests. However, full-spectrum CBG products may contain trace amounts of THC that could potentially cause a positive result.

Summary

CBG is a non-intoxicating cannabinoid that serves as the precursor to THC, CBD, and other cannabinoids. While preclinical research has identified potentially interesting properties—including antibacterial, neuroprotective, and inflammation-related effects—no human clinical trials have been completed. CBG products are becoming more available but remain more expensive than CBD due to the compound's low natural abundance. Consumers should understand that research is preliminary and no therapeutic uses have been established.

References

1. Degenhardt F, Stehle F, Kayser O. The biosynthesis of cannabinoids. In: Handbook of Cannabis and Related Pathologies. Academic Press; 2017:13-23.

1. de Meijer EPM, Hammond KM. The inheritance of chemical phenotype in Cannabis sativa L. (V): regulation of the propyl-/pentyl cannabinoid ratio, completion of a genetic map, and a test of sex-linked and autosomal varieties. Euphytica. 2016;210(2):291-310.

1. Navarro G, Varani K, Reyes-Resina I, et al. Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes. Front Pharmacol. 2018;9:632.

1. Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol. 2010;159(1):129-141.

1. Farha MA, El-Halfawy OM, Gale RT, et al. Uncovering the Hidden Antibiotic Potential of Cannabis. ACS Infect Dis. 2020;6(3):338-346.

1. Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O. Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics. 2015;12(1):185-199.

1. Borrelli F, Fasolino I, Romano B, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 2013;85(9):1306-1316.

1. Brierley DI, Samuels J, Duncan M, Whalley BJ, Williams CM. Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. Psychopharmacology (Berl). 2016;233(19-20):3603-3613.

1. Colasanti BK, Craig CR, Allara RD. Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol. Exp Eye Res. 1984;39(3):251-259.

1. National Conference of State Legislatures. State Industrial Hemp Statutes. https://www.ncsl.org/agriculture-and-rural-development/state-industrial-hemp-statutes (Updated 2024).

1. Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. J Clin Med. 2019;8(7):989.